Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):167-71. doi: 10.1016/j.jchromb.2005.06.031.

Abstract

A rapid and specific HPLC method has been developed and validated for simultaneous determination of clobazam, the anticonvulsant agent, and its major metabolite in human plasma. The sample preparation was a liquid-liquid extraction with tuloene yielding almost near 100% recoveries of two compounds. Chromatographic separation was achieved with a Chromolith Performance RP-18e 100 mm x 4.6mm column, using a mixture of a phosphate buffer (pH 3.5; 10mM)-acetonitrile (70:30, v/v), in isocratic mode at 2 ml/min at a detection wave-length of 228 nm. The calibration curves were linear (r(2)>0.998) in the concentration range of 5-450 ng ml(-1). The lower limit of quantification was 5 ng ml(-1) for two compounds studied. The within- and between-day precisions in the measurement of QC samples at four tested concentrations were in the range of 0.89-9.1% and 2.1-10.1% R.S.D., respectively. The developed procedure was applied to assess the pharmacokinetics of clobazam and its major metabolite following administration of a single 10mg oral dose of clobazam to healthy volunteers.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticonvulsants / blood*
  • Anticonvulsants / pharmacokinetics
  • Area Under Curve
  • Benzodiazepines / blood*
  • Benzodiazepines / metabolism
  • Benzodiazepines / pharmacokinetics
  • Biological Availability
  • Chromatography, High Pressure Liquid / methods*
  • Clobazam
  • Cross-Over Studies
  • Double-Blind Method
  • Half-Life
  • Humans
  • Reproducibility of Results

Substances

  • Anticonvulsants
  • Benzodiazepines
  • Clobazam
  • N-desmethylclobazam